1. Home
  2. TECX vs ABEO Comparison

TECX vs ABEO Comparison

Compare TECX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • ABEO
  • Stock Information
  • Founded
  • TECX 2019
  • ABEO 1974
  • Country
  • TECX United States
  • ABEO United States
  • Employees
  • TECX N/A
  • ABEO N/A
  • Industry
  • TECX
  • ABEO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TECX
  • ABEO Health Care
  • Exchange
  • TECX Nasdaq
  • ABEO Nasdaq
  • Market Cap
  • TECX 387.1M
  • ABEO 350.2M
  • IPO Year
  • TECX 2018
  • ABEO 1980
  • Fundamental
  • Price
  • TECX $16.01
  • ABEO $5.68
  • Analyst Decision
  • TECX Buy
  • ABEO Strong Buy
  • Analyst Count
  • TECX 6
  • ABEO 6
  • Target Price
  • TECX $79.17
  • ABEO $18.17
  • AVG Volume (30 Days)
  • TECX 475.2K
  • ABEO 756.4K
  • Earning Date
  • TECX 11-06-2025
  • ABEO 11-13-2025
  • Dividend Yield
  • TECX N/A
  • ABEO N/A
  • EPS Growth
  • TECX N/A
  • ABEO N/A
  • EPS
  • TECX N/A
  • ABEO 0.99
  • Revenue
  • TECX N/A
  • ABEO $400,000.00
  • Revenue This Year
  • TECX N/A
  • ABEO N/A
  • Revenue Next Year
  • TECX N/A
  • ABEO $324.71
  • P/E Ratio
  • TECX N/A
  • ABEO $5.74
  • Revenue Growth
  • TECX N/A
  • ABEO N/A
  • 52 Week Low
  • TECX $13.70
  • ABEO $3.93
  • 52 Week High
  • TECX $61.07
  • ABEO $7.54
  • Technical
  • Relative Strength Index (RSI)
  • TECX 34.36
  • ABEO 47.89
  • Support Level
  • TECX $15.92
  • ABEO N/A
  • Resistance Level
  • TECX $18.61
  • ABEO $6.95
  • Average True Range (ATR)
  • TECX 1.58
  • ABEO 0.24
  • MACD
  • TECX -0.46
  • ABEO -0.36
  • Stochastic Oscillator
  • TECX 5.59
  • ABEO 79.44

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Share on Social Networks: